LugnérAKKrabbePFM. An overview of the time trade-off method: concept, foundation, and the evaluation of distorting factors in putting a value on health. Expert Rev Pharmacoecon Outcomes Res. 2020;20(4):331–42.
2.
EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.
3.
JanssenBMFOppeMVersteeghMMStolkEA. Introducing the composite time trade-off: a test of feasibility and face validity. Eur J Health Econ. 2013;14(1):5–13.
4.
BusschbachJWeijnenTNieuwenhuizenM, et al. A comparison of EQ-5D time trade-off values obtained in Germany, the United Kingdom and Spain. In: BrooksRRabinRde CharroF, eds. The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective. New York: Springer; 2003. p. 143–65.
5.
GandhiMRandKLuoN.Valuation of health states considered to be worse than death—an analysis of composite time trade-off data from 5 EQ-5D-5L valuation studies. Value Health. 2019;22(3):370–6.
6.
Rand-HendriksenKAugestadLADahlFAKristiansenISStavemK.A shortcut to mean-based time tradeoff tariffs for the EQ-5D?Med Decis Making. 2012;32(4):569–77.
7.
DolanP.Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095–108.
8.
RoudijkBDondersRStalmeierP.A threshold explanation for the lack of variation in negative composite time trade-off values. Qual Life Res. 2022;31(9):2753–61.
9.
DolanPRobertsJ.To what extent can we explain time trade-off values from other information about respondents?Soc Sci Med. 2002;54(6):919–29.
10.
JakubczykM.Re-revisiting the utilities of health states worse than dead: the problem remains. Med Decis Making. 2023;43(7–8):875–85.
11.
VersteeghMMVermeulenKMEversSMAAde WitGAPrengerRStolkEA.Dutch tariff for the five-level version of EQ-5D. Value Health. 2016;19(4):343–52.
12.
HausmanJAWiseDA.Social experimentation, truncated distributions, and efficient estimation. Econometrica. 1977;45(4):919–38.
